Neurolief announced positive results from a clinical trial evaluating its neuromodulation for treatment-resistant depression (TRD). The non-invasive technology, designed for clinic and at-home treatment, could provide a new option for people who previously failed to respond to pharmaceutical treatments. Neurolief’s double-blind, randomized, placebo-controlled, multi-center clinical trial enrolled 124 patients across multiple centers in the U.S. […]
Neurolief
FDA clears Neurolief’s noninvasive neuromod tech to treat migraines
Neurolief today announced that it received FDA clearance for its Relivion noninvasive neuromodulation system to treat migraines. The noninvasive, multi-channel brain neuromodulation system’s creators designed it to treat acute migraines from home. It is a headset that administers personalized care to patients by delivering stimulation to six branches of the occipital and trigeminal nerves through […]
DTW Podcast: Vizient on PPE, Vicarious on VR-aided robotics and let’s all hope for pumpernickel
This week’s episode of DeviceTalks Weekly is brought to you by the later V, as in Vizient and Vicarious Surgical. Bharat Sundaram, COO and president of Vizient, will share how the healthcare supplier is strengthening the supply of PPE for hospitals. He’ll also reveal when the company expects to see US hospitals running at pre-COVID […]
The top 5 MassDevice stories of the week — August 14, 2020
COVID-19 continues to batter medical device companies — not to mention the world as a whole. But some of this week’s top five MassDevice stories demonstrate that medtech companies continue to innovate and ink business deals as they look toward a post-pandemic future. Want to hear more about the week’s top news? Executive editor Chris […]
Neurolief wins FDA breakthrough nod for wearable neuromod for depression
Neurolief announced today that it received FDA breakthrough device designation for its Relivion DP system for treating major depression. Relivion is a wearable, non-invasive, multi-channel brain neuromodulation device designed as an adjunctive treatment to pharmaceutical management of major depressive disorder (MDD) in adults who haven’t experienced satisfactory improvement from antidepressant medications, according to a news […]
